139 related articles for article (PubMed ID: 24369221)
41. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
Yoon JH; Kim JW; Jeon YW; Lee SE; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Park CW; Cho SG
Korean J Intern Med; 2015 May; 30(3):362-71. PubMed ID: 25995667
[TBL] [Abstract][Full Text] [Related]
42. Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.
Xia Y; Li ZM; Shi YX; Xia ZJ; Jiang WQ; Huang HQ
Ai Zheng; 2009 Feb; 28(2):146-9. PubMed ID: 19550126
[TBL] [Abstract][Full Text] [Related]
43. Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP.
Hara T; Tsurumi H; Goto N; Kanemura N; Yoshikawa T; Kasahara S; Yamada T; Sawada M; Goto H; Fukuno K; Kitagawa J; Yasuda I; Katsumura N; Takemura M; Takahashi T; Takami T; Moriwaki H
J Cancer Res Clin Oncol; 2009 Oct; 135(10):1421-8. PubMed ID: 19381687
[TBL] [Abstract][Full Text] [Related]
44. FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma.
Liu F; Ding H; Jin X; Ding N; Deng L; He Y; Zhu J; Song Y
DNA Cell Biol; 2014 Sep; 33(9):616-23. PubMed ID: 25050883
[TBL] [Abstract][Full Text] [Related]
45. Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with R-CHOP therapy.
Song MK; Chung JS; Sung-Yong O; Lee GW; Kim SG; Seol YM; Shin HJ; Choi YJ; Cho GJ; Shin DH; Yun EY
Ann Hematol; 2010 Oct; 89(10):985-91. PubMed ID: 20428871
[TBL] [Abstract][Full Text] [Related]
46. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.
Tanaka T; Shimada K; Yamamoto K; Hirooka Y; Niwa Y; Sugiura I; Kitamura K; Kosugi H; Kinoshita T; Goto H; Nakamura S
Ann Hematol; 2012 Mar; 91(3):383-90. PubMed ID: 21822617
[TBL] [Abstract][Full Text] [Related]
47. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Meyer PN; Fu K; Greiner T; Smith L; Delabie J; Gascoyne R; Ott G; Rosenwald A; Braziel R; Campo E; Vose J; Lenz G; Staudt L; Chan W; Weisenburger DD
Am J Clin Pathol; 2011 Jan; 135(1):54-61. PubMed ID: 21173124
[TBL] [Abstract][Full Text] [Related]
48. Polycomb protein EZH2 expression in diffuse large B-cell lymphoma is associated with better prognosis in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
Lee HJ; Shin DH; Kim KB; Shin N; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY
Leuk Lymphoma; 2014 Sep; 55(9):2056-63. PubMed ID: 24304372
[TBL] [Abstract][Full Text] [Related]
49. Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Yoo C; Lee DH; Kim JE; Jo J; Yoon DH; Sohn BS; Kim SW; Lee JS; Suh C
Ann Hematol; 2011 Jul; 90(7):797-802. PubMed ID: 21181163
[TBL] [Abstract][Full Text] [Related]
50. The modified Glasgow Prognostic Scores as a predictor in diffuse large B cell lymphoma treated with R-CHOP regimen.
Kim Y; Kim SJ; Hwang D; Jang J; Hyun SY; Kim YR; Kim JS; Min YH; Cheong JW
Yonsei Med J; 2014 Nov; 55(6):1568-75. PubMed ID: 25323893
[TBL] [Abstract][Full Text] [Related]
51. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.
Li ZM; Huang JJ; Xia Y; Zhu YJ; Zhao W; Wei WX; Jiang WQ; Lin TY; Huang HQ; Guan ZZ
Eur J Haematol; 2012 Jun; 88(6):510-7. PubMed ID: 22413767
[TBL] [Abstract][Full Text] [Related]
52. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
Yhim HY; Kim JS; Kang HJ; Kim SJ; Kim WS; Choi CW; Eom HS; Kim JA; Lee JH; Won JH; Shim H; Huh J; Lee DH; Suh C; Kwak JY
Int J Cancer; 2012 Jul; 131(1):235-43. PubMed ID: 21823120
[TBL] [Abstract][Full Text] [Related]
53. Serum soluble tumor necrosis factor receptor 1 level is associated with the outcome of diffuse large B-cell lymphoma patients treated with the CHOP or R-CHOP regimen.
Goto N; Tsurumi H; Takemura M; Matsumoto T; Shibata Y; Mabuchi R; Nakamura N; Nakamura H; Yamada T; Seishima M; Takami T; Takeuchi T; Moriwaki H
J Clin Exp Hematop; 2014; 54(2):117-27. PubMed ID: 25318944
[No Abstract] [Full Text] [Related]
54. Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
Keam B; Ha H; Kim TM; Jeon YK; Lee SH; Kim DW; Kim CW; Heo DS
Leuk Lymphoma; 2015 Jul; 56(7):2032-8. PubMed ID: 25382617
[TBL] [Abstract][Full Text] [Related]
55. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
56. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era.
Takahashi H; Tomita N; Yokoyama M; Tsunoda S; Yano T; Murayama K; Hashimoto C; Tamura K; Sato K; Ishigatsubo Y
Cancer; 2012 Sep; 118(17):4166-72. PubMed ID: 22213346
[TBL] [Abstract][Full Text] [Related]
57. Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone.
Goto N; Tsurumi H; Takemura M; Kanemura N; Kasahara S; Hara T; Yasuda I; Shimizu M; Yamada T; Sawada M; Takahashi T; Yamada T; Seishima M; Moriwaki H; Takami T
Leuk Lymphoma; 2012 Aug; 53(8):1494-500. PubMed ID: 22280534
[TBL] [Abstract][Full Text] [Related]
58. Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma.
Porrata LF; Ristow KM; Habermann TM; Witzig TE; Colgan JP; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Nowakowski G; Thompson CA; Markovic SN
Leuk Lymphoma; 2014 Dec; 55(12):2728-38. PubMed ID: 24547705
[TBL] [Abstract][Full Text] [Related]
59. High Ki-67 expression in involved bone marrow predicts worse clinical outcome in diffuse large B cell lymphoma patients treated with R-CHOP therapy.
Song MK; Chung JS; Lee JJ; Yang DH; Kim IS; Shin DH; Shin HJ
Int J Hematol; 2015 Feb; 101(2):140-7. PubMed ID: 25504496
[TBL] [Abstract][Full Text] [Related]
60. Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expression.
Li Y; Yimamu M; Wang X; Zhang X; Mao M; Fu L; Aisimitula A; Nie Y; Huang Q
Int J Hematol; 2014 Jan; 99(1):79-86. PubMed ID: 24258714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
